Registered number: 09290866

APOTECHNOS LIMITED

UNAUDITED

AMENDED FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 30 JUNE 2020



APOTECHNOS LIMITED REGISTERED NUMBER: 09290866

BALANCE SHEET AS AT 30 JUNE 2020

			·		
	Note		2020 £		2019 £
FIXED ASSETS					
Intangible assets	4		5,000		5,000
			5,000	,	5,000
Creditors: amounts falling due within one year	5	(36,280)		(36,280)	
NET CURRENT LIABILITIES	•	****	(36,280)		(36,280)
TOTAL ASSETS LESS CURRENT LIABILITIES			(31,280)		(31,280)
NET LIABILITIES			(31,280)		(31,280)
CAPITAL AND RESERVES					
Called up share capital	6		-		-
Profit and loss account			(31,280)		(31,280)
			(31,280)		(31,280)

For the year ended 30 June 2020 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

APOTECHNOS LIMITED REGISTERED NUMBER: 09290866

BALANCE SHEET (CONTINUED) AS AT 30 JUNE 2020

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

Dominic Quennell

Director Date: 28 = April 2021

The notes on pages 3 to 4 form part of these financial statements.

APOTECHNOS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

1. GENERAL INFORMATION

Apotechnos Limited is a private Company limited by shares and incorporated in England and Wales. Its registered office is 19 Kingsmill Business Park, Chapel Mill Road, Kingston-Upon-Thames, Surrey, KT1 3GZ.

The Company has not traded during the year. During this period, the Company received no income and incurred no expenditure and therefore made neither profit or loss.

The Company's functional and presentational currency is GBP.

2. ACCOUNTING POLICIES

2.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

2.2 GOING CONCERN

The directors have considered the going concern basis of preparation of the financial statements, noting the net current liabilities position at the balance sheet date. The Company has been financed to date by its parent entity which has indicated its ongoing financial support to allow the Company to continue in operational existence for the foreseeable future, being a period of at least 12 months from the date of approval of these financial statements. The directors have therefore concluded that it is appropriate to continue to adopt the going concern basis.

2.3 INTANGIBLE ASSETS .

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

Amortisation is charged from the date the intangible asset is available for use.

2.4 CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.5 CREDITORS

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

APOTECHNOS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

3. EMPLOYEES

The Company has no employees other than the directors, who did not receive any remuneration (2019 - £NIL).

The average monthly number of employees, including directors, during the year was 0 (2019 - 0).

4. INTANGIBLE ASSETS

			Patents £
	COST		·
	At 1 July 2019	•	5,000
	At 30 June 2020	. -	5,000
	NET BOOK VALUE		
	At 30 June 2020		5,000
	At 30 June 2019	=	5,000
5.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		
		2020 £	2019 £
	Amounts owed to group undertakings	35,267	35,267
	Other creditors	1,013	1,013
		36,280	36,280
	Amounts owed to group undertakings are unsecured, interest free and rep	payable on demand.	
6.	SHARE CAPITAL		
	•	2020	2019
	ALLOTTED, CALLED UP AND FULLY PAID	£	£
	1 (2019 - 1) Ordinary share of £0.01	-	<u>-</u>